Affiliation:
1. Katedra i Zakład Farmakologii Klinicznej, Uniwersytet Medyczny im. Piastów Śląskich, Wrocław, Poland
Abstract
Pharmacovigilance is an important aspect of depression treatment, considering that 40–90% of patients experience side effects of antidepressant use. This paper discusses the issues of optimising the use of venlafaxine, including its pharmacodynamic and pharmacokinetic properties, indications, adverse effects and risk factors for their occurrence, such as co-morbidities or genetic polymorphisms and interactions with other drugs.
Publisher
Institute of Psychiatry and Neurology